The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Treatment facility volume-outcome relationship exists in Waldenström’s
Waldenström’s Macroglobulinemia (WM) is a rare disease; therefore, a general hematologist-oncologist’s experience of the management of WM is likely to be limited. Here, Jonas Paludo, MD, of the Mayo Clinic, Rochester, MN, discusses the relationship between treatment facility volume and outcomes in WM, from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. This revealed that patients treated initially at higher volume facilities had a lower risk of mortality.
